BiotechTube
Home/Pipeline/Stem Cell Program

Stem Cell Program

ALS

ResearchActive

Key Facts

Indication
ALS
Phase
Research
Status
Active
Company
BioArctic

About BioArctic

BioArctic is a research-driven biopharma company with a mission to develop transformative treatments for neurodegenerative diseases. Its strategic partnership with Eisai led to the landmark approval and commercialization of lecanemab for Alzheimer's, providing a foundational revenue stream. The company's core strategy is to leverage its proprietary BrainTransporter™ platform to build a diversified pipeline of next-generation biologics for Parkinson's and ALS, while continuing to advance its Alzheimer's franchise.

View full company profile

Therapeutic Areas

Alzheimer's DiseaseParkinson's DiseaseALS

Other ALS Drugs

DrugCompanyPhase
Eolo40 NCEEolo PharmaDiscovery
New targets programTreewayPreclinical
SYF2 ProgramAcuraStemDiscovery
Target-03Verge GenomicsDiscovery
Target-04Verge GenomicsDiscovery
BIIB105 (ATXN2 ASO)BiogenPhase 2
Undisclosed ProgramBioArctic ABDiscovery